As winter approaches, the prospect of warding off both influenza and COVID-19 with a single shot is moving closer to reality. Moderna has received a positive opinion from the European Medicines Agency (EMA) for its mCombriax vaccine, a combined vaccine designed to protect individuals aged 50 and older against both viruses. This development offers a potential simplification of the annual vaccination process, addressing concerns about the inconvenience of receiving separate doses.
The potential for a combined vaccine comes as public health officials continue to emphasize the importance of vaccination against both respiratory illnesses. While annual influenza vaccination is widely recommended, uptake rates for COVID-19 boosters have been lower, with only 15% of individuals over 65 in France receiving a COVID-19 vaccine between October 2025 and December 31, 2025, despite health ministry recommendations for simultaneous administration of both vaccines, according to reporting from Le Parisien. Influenza vaccination rates for those over 65 reached 53% during the same period.
The mCombriax vaccine utilizes messenger RNA (mRNA) technology, a platform that has proven effective in the development of COVID-19 vaccines. The EMA’s assessment considered the vaccine’s efficacy against the SARS-CoV-2 strain recommended for the 2023/2024 season and influenza strains aligned with the World Health Organization’s (WHO) 2023/2024 recommendations. The EMA’s positive opinion paves the way for potential market authorization across Europe.
Addressing Vaccine Hesitancy and Convenience
The development of a combined vaccine addresses a common concern expressed by individuals like Élisabeth, who, according to Le Parisien, preferred to space out her influenza and COVID-19 vaccinations, fearing a potentially amplified experience of side effects. This preference led her to receive the influenza vaccine earlier in the vaccination campaign, with the possibility of delaying or foregoing the COVID-19 vaccine altogether. The combined vaccine offers a solution for those who prefer a more streamlined approach.
How the mCombriax Vaccine Works
mCombriax works by presenting the body with mRNA instructions to build proteins found on the surface of both the influenza virus and SARS-CoV-2. This triggers an immune response, preparing the body to defend against future infection. The EMA’s review focused on the vaccine’s safety and efficacy, evaluating data from clinical trials to ensure it meets the agency’s rigorous standards. The agency’s assessment is a crucial step before the vaccine can be made available to the public.
The Impact of Combined Vaccination
A combined vaccine could significantly improve vaccination rates and reduce the burden of both influenza and COVID-19, particularly among vulnerable populations. Simplifying the vaccination process may encourage more individuals to receive protection against both viruses, potentially leading to fewer hospitalizations and severe illnesses. The EMA’s approval would mark a significant advancement in preventative medicine, offering a more convenient and comprehensive approach to respiratory virus protection.
The 2025-2026 influenza and COVID-19 vaccination campaign in France concluded on February 28th, but the availability of a combined vaccine is anticipated for future seasons. The success of this approach will likely be monitored closely by health authorities worldwide, potentially influencing vaccination strategies globally.
What remains to be seen is how quickly the vaccine will be rolled out across European member states following potential market authorization and how public acceptance of the combined vaccine will compare to individual vaccinations. Further data on the long-term efficacy and safety of mCombriax will also be crucial in informing future vaccination recommendations.
Have your say: Do you think a combined flu and COVID-19 vaccine will encourage more people to get vaccinated? Share your thoughts in the comments below.
Disclaimer: This article provides informational content about health and medicine and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
